NeoGenomics (NASDAQ:NEO) Releases FY 2024 Earnings Guidance

NeoGenomics (NASDAQ:NEO) updated its FY 2024 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 0.020-0.070 for the period, compared to the consensus estimate of 0.020. The company issued revenue guidance of $655.0 million-$667.0 million, compared to the consensus revenue estimate of $655.3 million.

Analyst Ratings Changes

NEO has been the subject of a number of analyst reports. Craig Hallum began coverage on NeoGenomics in a report on Wednesday, May 1st. They issued a buy rating and a $26.00 price target for the company. BTIG Research reduced their target price on NeoGenomics from $23.00 to $21.00 and set a buy rating for the company in a research note on Thursday, May 2nd. Benchmark reissued a buy rating and set a $18.00 price target on shares of NeoGenomics in a research report on Wednesday, May 1st. Needham & Company LLC cut their price target on shares of NeoGenomics from $24.00 to $19.00 and set a buy rating on the stock in a report on Tuesday, April 30th. Finally, TD Cowen reduced their price objective on shares of NeoGenomics from $21.00 to $20.00 and set a buy rating on the stock in a research note on Wednesday, May 1st. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $19.78.

NeoGenomics Stock Performance

NEO stock traded down $0.24 during trading on Monday, hitting $14.64. 1,223,976 shares of the company’s stock traded hands, compared to its average volume of 836,748. The stock has a fifty day moving average price of $13.93 and a two-hundred day moving average price of $14.69. The company has a quick ratio of 7.22, a current ratio of 7.48 and a debt-to-equity ratio of 0.58. NeoGenomics has a 52 week low of $11.03 and a 52 week high of $21.22. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of -22.55 and a beta of 1.19.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, April 30th. The medical research company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). NeoGenomics had a negative return on equity of 3.54% and a negative net margin of 13.79%. The business had revenue of $156.24 million for the quarter, compared to analyst estimates of $149.82 million. As a group, equities analysts anticipate that NeoGenomics will post -0.21 EPS for the current fiscal year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.